Recent studies have also shown that combination treatment of CDK4/6 inhibitors with ICBs exhibits a synergistic effect on tumor control, suggesting that combining these therapies is a remarkable strategy for expanding ICB utility [37,38]. Here, CDK4 is linked to neoplasm.